

Forteo[®] (teriparatide) – First-time generic

- On November 17, 2023, [Teva announced](#) the FDA approval of an AB-rated generic version of Eli Lilly's [Forteo \(teriparatide\)](#) subcutaneous injection.
 - Teva's generic Forteo is expected to be available in the coming weeks.
- Forteo is approved:
 - For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy
 - To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy and
 - For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.
- Teriparatide is also available as a subcutaneous injection by [Alvogen](#) and carries the same indications as Forteo.
- According to IQVIA data, Forteo had annual sales of \$609 million as of July 2023.